Developer docs
API playgroundTry for free, no card

Search company profiles

biomodal

Full company profile

uuid0006unw

Namestring
biomodal
Legal namestring
biomodal
Websiteurl
biomodal.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

biomodal (formerly Cambridge Epigenetix until a 2023 rebrand) is a UK-based life-sciences tools company founded in 2013 by Prof. Sir Shankar Balasubramanian and Bobby Yerramilli-Rao. The company has developed a proprietary hairpin-adaptor chemistry that enables simultaneous sequencing of all four canonical DNA bases (A, C, G, T) together with the two principal epigenetic modifications, 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), producing what the company markets as a 6-base genome from a single 5ng DNA sample in a single experiment at Q40+ base-call accuracy. Productized under the duet multiomics solution brand, the portfolio includes the duet evoC kit (true 6-base resolution), the duet +modC kit (5-base resolution), the duet UDIs multiplex indexing kits, the duet post-sequencing analysis software, and the modality XPLR low-code analysis software.

Revenue is generated primarily through quote-based sales of consumable kits and software to academic institutions, cancer research hospitals, pharmaceutical and biotech R&D groups, and clinical laboratories. Additional monetization channels include a Certified Service Provider network of 8 validated service organizations across the US, Canada, Australia, and Germany; OEM and white-label partnerships via the Custom Solutions program; and licensing/royalty arrangements associated with tailored assay development. biomodal operates a 51–100 person team headquartered at Chesterford Research Park near Cambridge, UK, with a US office in Carlsbad, California, and was backed by a $98 million financing in 2021 from GV, Temasek, Syncona, Ahren, and New Science Ventures. Customers include the British Columbia Cancer Centre, Peter MacCallum Cancer Centre, Vanderbilt University Medical Center, University College London, Johns Hopkins, the National Cancer Institute, Medical University of Graz, and La Jolla Institute for Immunology, spanning cancer research, neurodegenerative disease, aging, liquid biopsy, and precision-medicine applications.

Short descriptiontext

biomodal is a UK-based life-sciences tools company that commercializes proprietary 6-base genome sequencing kits and software, enabling simultaneous detection of canonical DNA bases plus 5mC and 5hmC epigenetic modifications for academic, pharmaceutical, and clinical-research customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
DNA sequencing technology, multiomics solutions, epigenetic sequencing, genomics research tools, liquid biopsy assays
Industry3 codes
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
Product category
DNA Sequencing Tools
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1duet evoC product sales
TypeOne Time License
Description

Sale of duet multiomics solution evoC kits (8-reaction kit product code 6205, 24-reaction kit product code 6206) that include the duet evoC assay library preparation reagents and duet software for genetic and epigenetic analysis.

biomodal.com
2duet +modC product sales
TypeOne Time License
Description

Sale of duet multiomics solution +modC kits (8-reaction kit product code 5205, 24-reaction kit product code 5206) for customers requiring 5-base resolution (canonical bases + modified C) without distinguishing 5mC from 5hmC.

biomodal.com
3modality XPLR software
TypeSubscription Recurring
Description

Software for analyzing 6-base sequencing data. Bundled with duet kits but also available as standalone product for processing and visualizing multiomic data.

biomodal.com
4Custom solutions and OEM partnerships
TypeLicensing Royalties
Description

Partner with customers to create tailored workflows, kits, and integrated solutions including purpose-built assay development, tailored product optimization, flexible formatting, and co-branded or white-label commercial products.

biomodal.com
5Certified Service Provider network
TypeTransaction Fee
Description

Validated service organizations worldwide offer duet multiomics sequencing services using biomodal's technology, expanding market reach through a channel model.

biomodal.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure, Others
Pricing details4 tiers
1duet multiomics solution evoC 8-reaction kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Includes duet evoC assay (pre-sequencing workflow with hairpin technology) and duet software. Product code 6205.

biomodal.com
2duet multiomics solution evoC 24-reaction kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Larger kit format for higher throughput. Product code 6206.

biomodal.com
3duet multiomics solution +modC 8-reaction kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Includes duet +modC assay and duet software. Product code 5205.

biomodal.com
4duet multiomics solution +modC 24-reaction kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Larger kit format. Product code 5206.

biomodal.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

biomodal develops and sells the duet multiomics solution, a sequencing chemistry and software platform that simultaneously reads the four canonical DNA bases together with the epigenetic modifications 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) from a single low-input DNA sample in a single workflow. Its commercial products are the duet evoC kit (true 6-base genome, 5ng input) and the duet +modC kit (5-base genome, 10ng input), supported by duet software for post-sequencing analysis and the modality XPLR software for multiomic data exploration, all compatible with Illumina and Element Biosciences sequencers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • AUC of 0.95 for stage I colorectal cancer detection from liquid biopsy using 6-base sequencing
+3 more records
Product overview1 text field

biomodal offers a portfolio of multiomics products centered on the duet multiomics solution platform for 6-base genome sequencing. The core offerings include duet multiomics solution evoC (distinguishes 5mC and 5hmC for true 6-base genome) and duet multiomics solution +modC (detects modified cytosine alongside genetic bases). Supporting these assays are duet software for post-sequencing analysis (deployable on-premises or cloud) and modality XPLR software for visualization and differential analysis. Custom solutions are available for partners requiring tailored workflows. The platform integrates with Illumina and Element Biosciences sequencing instruments and is supported by a Certified Service Provider network.

Product and service6 records
1duet multiomics solution evoC
CategorySequencing reagent kit
Description

A true 6-base genome sequencing kit that distinguishes all four canonical DNA bases (A, C, G, T) plus 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) at single-base resolution from a single 5ng DNA sample in a single experiment, sold in 8-reaction (product code 6205) and 24-reaction (product code 6206) kit formats and bundled with duet software; targeted at cancer, neurodegeneration, ageing and liquid biopsy researchers on Illumina or Element Biosciences sequencers.

2duet multiomics solution +modC
CategorySequencing reagent kit
Description

A 5-base genome sequencing kit that measures the four canonical bases without ambiguity in C or T calls plus modified cytosine (modC) using existing NGS pipelines phased within a single read, requiring only 10ng of DNA input; available in 8-reaction (product code 5205) and 24-reaction (product code 5206) kit formats with duet software, intended for epigenetic and genetic analysis on standard sequencers.

3modality XPLR
CategoryBioinformatics software
Description

High-performance, low-code analysis software for 6-base sequencing data that transforms raw sequencing counts into multiomic model-ready features with biological QC, differential methylation analysis, feature extraction and publication-ready visualizations; bundled with duet kits and also available as a standalone recurring subscription, running on a standard laptop.

4duet software
CategoryBioinformatics software
Description

Post-sequencing analysis software that processes sequencing data through read resolution, genome alignment, variant calling and epigenetic quantification, providing complete genetic data plus methylation data at single-base resolution; deployable on-premises or in the cloud and bundled with the duet multiomics solution kits.

5Custom Solutions
CategoryService offering
Description

Tailored workflow, kit and integrated solution development service offering purpose-built assay development, tailored product optimization, flexible formatting, and co-branded or white-label commercial products built around biomodal's multiomics technology for partners and large customers.

6duet UDIs (Unique Dual Indexes)
CategorySequencing accessory reagent
Description

Unique dual index kits for multiplexing samples on the duet multiomics workflow, available in 1-8 (product code 4103), 1-24 (product code 4102) and 1-96 (product code 4104) reaction kit sizes as a complementary reagent for kit customers.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-23
Description

biomodal announced at AGBT 2026 General Meeting that its duet multiomic solutions are now compatible with Element Biosciences' AVITI24 and AVITI sequencing instruments. Validation conducted at the University of Minnesota Genomics Center. The collaboration enables complete methylation detection on Element platforms, combining biomodal's 5-base and 6-base sequencing solutions with Element's high-throughput sequencing systems for streamlined end-to-end workflows.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2026-02-23
Description

Validation partner for Element Biosciences compatibility testing. Conducts validation studies to verify duet multiomic solutions work correctly on Element sequencing instruments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

Zymo Research partnered with biomodal to integrate biomodal's multiomics technology into Zymo's NGS Services platform, enabling analysis of multiple DNA modifications from a single library. Collaboration aims to advance epigenetics research and promote insights into gene regulation, disease mechanisms, and cellular function. Combined offering accelerates research in oncology, neurobiology, aging, and precision medicine.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

biomodal

DNA Sequencing Toolsbiomodal.com

biomodal is a UK-based life-sciences tools company that commercializes proprietary 6-base genome sequencing kits and software, enabling simultaneous detection of canonical DNA bases plus 5mC and 5hmC epigenetic modifications for academic, pharmaceutical, and clinical-research customers.

What biomodal does

biomodal (formerly Cambridge Epigenetix until a 2023 rebrand) is a UK-based life-sciences tools company founded in 2013 by Prof. Sir Shankar Balasubramanian and Bobby Yerramilli-Rao. The company has developed a proprietary hairpin-adaptor chemistry that enables simultaneous sequencing of all four canonical DNA bases (A, C, G, T) together with the two principal epigenetic modifications, 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), producing what the company markets as a 6-base genome from a single 5ng DNA sample in a single experiment at Q40+ base-call accuracy. Productized under the duet multiomics solution brand, the portfolio includes the duet evoC kit (true 6-base resolution), the duet +modC kit (5-base resolution), the duet UDIs multiplex indexing kits, the duet post-sequencing analysis software, and the modality XPLR low-code analysis software.

Revenue is generated primarily through quote-based sales of consumable kits and software to academic institutions, cancer research hospitals, pharmaceutical and biotech R&D groups, and clinical laboratories. Additional monetization channels include a Certified Service Provider network of 8 validated service organizations across the US, Canada, Australia, and Germany; OEM and white-label partnerships via the Custom Solutions program; and licensing/royalty arrangements associated with tailored assay development. biomodal operates a 51–100 person team headquartered at Chesterford Research Park near Cambridge, UK, with a US office in Carlsbad, California, and was backed by a $98 million financing in 2021 from GV, Temasek, Syncona, Ahren, and New Science Ventures. Customers include the British Columbia Cancer Centre, Peter MacCallum Cancer Centre, Vanderbilt University Medical Center, University College London, Johns Hopkins, the National Cancer Institute, Medical University of Graz, and La Jolla Institute for Immunology, spanning cancer research, neurodegenerative disease, aging, liquid biopsy, and precision-medicine applications.

biomodal firmographics

Firmographics
Name
biomodal
Legal name
biomodal
Website
https://biomodal.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
biomodal is a UK-based life-sciences tools company that commercializes proprietary 6-base genome sequencing kits and software, enabling simultaneous detection of canonical DNA bases plus 5mC and 5hmC epigenetic modifications for academic, pharmaceutical, and clinical-research customers.
Ownership category
akta.pro rank

biomodal industry classification

Industry
Product category
DNA Sequencing Tools
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • DNA sequencing technology
  • Multiomics solutions
  • Epigenetic sequencing
  • Genomics research tools
  • Liquid biopsy assays

Where biomodal is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

biomodal business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure, Others

Revenue model

  1. duet evoC product sales: Sale of duet multiomics solution evoC kits (8-reaction kit product code 6205, 24-reaction kit product code 6206) that include the duet evoC assay library preparation reagents and duet software for genetic and epigenetic analysis.
  2. duet +modC product sales: Sale of duet multiomics solution +modC kits (8-reaction kit product code 5205, 24-reaction kit product code 5206) for customers requiring 5-base resolution (canonical bases + modified C) without distinguishing 5mC from 5hmC.
  3. modality XPLR software: Software for analyzing 6-base sequencing data. Bundled with duet kits but also available as standalone product for processing and visualizing multiomic data.
  4. Custom solutions and OEM partnerships: Partner with customers to create tailored workflows, kits, and integrated solutions including purpose-built assay development, tailored product optimization, flexible formatting, and co-branded or white-label commercial products.
  5. Certified Service Provider network: Validated service organizations worldwide offer duet multiomics sequencing services using biomodal's technology, expanding market reach through a channel model.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goduet multiomics solution evoC 8-reaction kit
Unit PricingPay-as-you-goduet multiomics solution evoC 24-reaction kit
Unit PricingPay-as-you-goduet multiomics solution +modC 8-reaction kit
Unit PricingPay-as-you-goduet multiomics solution +modC 24-reaction kit

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

biomodal product offering

Product offering

Core offering

biomodal develops and sells the duet multiomics solution, a sequencing chemistry and software platform that simultaneously reads the four canonical DNA bases together with the epigenetic modifications 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) from a single low-input DNA sample in a single workflow. Its commercial products are the duet evoC kit (true 6-base genome, 5ng input) and the duet +modC kit (5-base genome, 10ng input), supported by duet software for post-sequencing analysis and the modality XPLR software for multiomic data exploration, all compatible with Illumina and Element Biosciences sequencers.

Product overview

biomodal offers a portfolio of multiomics products centered on the duet multiomics solution platform for 6-base genome sequencing. The core offerings include duet multiomics solution evoC (distinguishes 5mC and 5hmC for true 6-base genome) and duet multiomics solution +modC (detects modified cytosine alongside genetic bases). Supporting these assays are duet software for post-sequencing analysis (deployable on-premises or cloud) and modality XPLR software for visualization and differential analysis. Custom solutions are available for partners requiring tailored workflows. The platform integrates with Illumina and Element Biosciences sequencing instruments and is supported by a Certified Service Provider network.

Differentiator

Problem solved

Functional benefit

Products and services

  • duet multiomics solution evoC A true 6-base genome sequencing kit that distinguishes all four canonical DNA bases (A, C, G, T) plus 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) at single-base resolution from a single 5ng DNA sample in a single experiment, sold in 8-reaction (product code 6205) and 24-reaction (product code 6206) kit formats and bundled with duet software; targeted at cancer, neurodegeneration, ageing and liquid biopsy researchers on Illumina or Element Biosciences sequencers.
  • duet multiomics solution +modC A 5-base genome sequencing kit that measures the four canonical bases without ambiguity in C or T calls plus modified cytosine (modC) using existing NGS pipelines phased within a single read, requiring only 10ng of DNA input; available in 8-reaction (product code 5205) and 24-reaction (product code 5206) kit formats with duet software, intended for epigenetic and genetic analysis on standard sequencers.
  • modality XPLR High-performance, low-code analysis software for 6-base sequencing data that transforms raw sequencing counts into multiomic model-ready features with biological QC, differential methylation analysis, feature extraction and publication-ready visualizations; bundled with duet kits and also available as a standalone recurring subscription, running on a standard laptop.
  • duet software Post-sequencing analysis software that processes sequencing data through read resolution, genome alignment, variant calling and epigenetic quantification, providing complete genetic data plus methylation data at single-base resolution; deployable on-premises or in the cloud and bundled with the duet multiomics solution kits.
  • Custom Solutions Tailored workflow, kit and integrated solution development service offering purpose-built assay development, tailored product optimization, flexible formatting, and co-branded or white-label commercial products built around biomodal's multiomics technology for partners and large customers.
  • duet UDIs (Unique Dual Indexes) Unique dual index kits for multiplexing samples on the duet multiomics workflow, available in 1-8 (product code 4103), 1-24 (product code 4102) and 1-96 (product code 4104) reaction kit sizes as a complementary reagent for kit customers.

Quantifiable outcome

  • AUC of 0.95 for stage I colorectal cancer detection from liquid biopsy using 6-base sequencing
  • +3 more outcomes

Companies that use biomodal

Customer profile

Named customers9 records

Segments7 records

Ideal customer profiles3 records

biomodal technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature6 records

biomodal partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • Element BiosciencescoreTechnology or Integration · 23 February 2026biomodal announced at AGBT 2026 General Meeting that its duet multiomic solutions are now compatible with Element Biosciences' AVITI24 and AVITI sequencing instruments. Validation conducted at the University of Minnesota Genomics Center. The collaboration enables complete methylation detection on Element platforms, combining biomodal's 5-base and 6-base sequencing solutions with Element's high-throughput sequencing systems for streamlined end-to-end workflows.
  • University of Minnesota Genomics CentersupportingTechnology or Integration · 23 February 2026Validation partner for Element Biosciences compatibility testing. Conducts validation studies to verify duet multiomic solutions work correctly on Element sequencing instruments.
  • Zymo ResearchcoreStrategic or Co-development Partner · 19 November 2025Zymo Research partnered with biomodal to integrate biomodal's multiomics technology into Zymo's NGS Services platform, enabling analysis of multiple DNA modifications from a single library. Collaboration aims to advance epigenetics research and promote insights into gene regulation, disease mechanisms, and cellular function. Combined offering accelerates research in oncology, neurobiology, aging, and precision medicine.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

biomodal competitors and assessment

Company assessment

Market position

Strengths5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

biomodal social profiles

Digital presence

biomodal financial estimates

Financial estimate

Revenue estimate

Valuation estimate

biomodal leadership team

Management profile

Number of profiles

Profiles11 records

biomodal funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

biomodal M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about biomodal

What does biomodal do?

biomodal develops and sells the duet multiomics solution, a sequencing chemistry and software platform that simultaneously reads the four canonical DNA bases together with the epigenetic modifications 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) from a single low-input DNA sample in a single workflow. Its commercial products are the duet evoC kit (true 6-base genome, 5ng input) and the duet +modC kit (5-base genome, 10ng input), supported by duet software for post-sequencing analysis and the modality XPLR software for multiomic data exploration, all compatible with Illumina and Element Biosciences sequencers.

Is biomodal a public or private company?

biomodal is a private company. It is classified as venture growth investor backed and is currently operating.

When was biomodal founded?

biomodal was founded in 2013. It employs 51 to 100 people.

Where is biomodal based?

biomodal is headquartered in Cambridge, United Kingdom, in the Europe region.

How does biomodal make money?

Five revenue lines are on record. duet evoC product sales are the primary driver. The others are duet +modC product sales, modality XPLR software, custom solutions and OEM partnerships and certified Service Provider network.

Does biomodal have an API?

No public API is recorded for biomodal.

What industry is biomodal in?

biomodal's product category is DNA Sequencing Tools. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyBiomodal launches new DNA testing workflows to improve early cancer detectionBiomodal has launched the duet mosaic family, a new set of circulating cell-free DNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. These integrated kits combine genetic, epigenetic, and fragmentomic data analysis to improve early cancer detection and biomarker discovery capabilities. The company cites data from the European Association for Cancer Research indicating that these methods lower limits of detection compared to traditional conversion-based techniques.FinancialContent Business Pagebiomodal Launches duet mosaic Giving Liquid Biopsy Researchers and Developers More Signal from Every Blood Drawbiomodal announced the launch of the duet mosaic family, consisting of two new cfDNA-optimized multiomic sequencing workflows designed for liquid biopsy and translational research. These tools enable researchers to extract genetic, epigenetic, and fragmentomic data from a single sample in one integrated workflow, addressing the need for multi-signal approaches in early cancer detection. The products are available immediately in various reaction formats and include proprietary software pipelines for data analysis.BioSpacebiomodal Launches duet mosaic Giving Liquid Biopsy Researchers and Developers More Signal from Every Blood Drawbiomodal launched the duet mosaic family of cfDNA-optimized multiomic sequencing workflows, including duet +modC and duet 6-base mosaic, to generate genetic, epigenetic, and fragmentomic data from a single sample. The company cites EACR data showing combined signals improve detection limits and classification. The kits are available now for research use.Business Wire Blogbiomodal Launches duet mosaic Giving Liquid Biopsy Researchers and Developers More Signal from Every Blood Drawbiomodal launched the duet mosaic family, which includes new multiomic sequencing workflows optimized for liquid biopsy, designed to enhance data collection from limited blood samples. The workflow integrates genetic, epigenetic, and fragmentomic information, improving detection rates for cancer and biomarker discovery. The duet mosaic kits are now available for research use in various reaction formats.BioSpacebiomodal and Element Biosciences Combine Duet Multiomic and High-Throughput Sequencing Capabilities to Advance Clinical Researchbiomodal announced at the AGBT 2026 General Meeting that its duet multiomic solutions are now compatible with Element Biosciences' AVITI24 and AVITI sequencing instruments, with validation conducted at the University of Minnesota Genomics Center. The collaboration combines biomodal's 5-base and 6-base sequencing solutions with Element's sequencing systems, enabling complete methylation detection on Element platforms and delivering a streamlined end-to-end workflow for next-generation sequencing. Both companies aim to accelerate clinical research in cancer, aging, and neurodegenerative diseases by helping researchers convert NGS data into actionable insights.Longevity.TechnologyZymo Research and biomodal partner to offer advanced multi-omic sequencingZymo Research has entered a strategic partnership with biomodal to integrate biomodal's "duet" multiomics technology into Zymo's NGS Services platform, making Zymo an authorized provider of biomodal's evoC and +modC assays. The integration enables simultaneous analysis of 5-methylcytosine, 5-hydroxymethylcytosine, and standard DNA bases from a single DNA library, allowing researchers to capture both genetic and regulatory information in one workflow. Both companies expect this combined offering to accelerate research in oncology, neurobiology, aging, and precision medicine.PR NewswireZymo Research Announces Strategic Partnership with biomodal to Deliver Next-Gen Multiomic InsightsZymo Research, a global leader in next-generation sequencing based in Irvine, California, has announced a strategic partnership with biomodal, an omics-based life sciences technology company. Under the agreement, Zymo Research's NGS Services division becomes a certified provider of biomodal's duet multiomics solutions, enabling simultaneous analysis of 5hmC, 5mC, and genetic sequence from a single DNA library. This collaboration aims to advance epigenetics and biomedical research across oncology, neurobiology, aging, and precision medicine by providing researchers with comprehensive genetic and epigenetic insights.PR NewswireZymo Research Announces Strategic Partnership with biomodal to Deliver Next-Gen Multiomic InsightsZymo Research has entered a strategic partnership with biomodal, becoming a certified provider (bCSP) of biomodal's duet multiomics solutions for its NGS Services division. The partnership enables simultaneous analysis of 5hmC, 5mC, and genetic sequence from a single DNA library, representing what the companies describe as a major technological innovation in epigenetics. This collaboration supports research across oncology, neurobiology, aging, and precision medicine by providing the scientific community access to the full 6-base genome.Longevity.TechnologyBiomodal launches certified service network for Duet multiomics sequencingBiomodal has launched a Certified Service Provider (CSP) program to expand global access to its Duet multiomics sequencing solutions, establishing a network of validated organizations trained and certified to deliver multiomic data services. Initial participants in the program include eight prominent research service providers across the USA, Australia, Germany, and Canada. The launch is intended to scale adoption of the multiomics platform while maintaining standardization and quality consistency across service sites.